Peitao Zhou

Peitao Zhou

Auto-generated profile, based on publicly available information

Peitao Zhou

Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2024 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
YSYining Sun
Yining Sun
PZPeitao Zhou
Peitao Zhou
JQJunying Qian
Junying Qian
QZQin Zeng
Qin Zeng
GWGuangyan Wei
Guangyan Wei
YFYuan Fang
Yuan Fang

19 March 2024 in Research Square
Verified
Preprint
Open access
PDF file
YFYuan Fang
Yuan Fang
YSYining Sun
Yining Sun
PZPeitao Zhou
Peitao Zhou
QZQin Zeng
Qin Zeng
JQJunying Qian
Junying Qian
DWDehua Wu
Dehua Wu
Disturbances in tumor cell metabolism reshape the tumor microenvironment (TME) and impair antitumor immunity, but the implicit mechanisms remain elusive. Here, we found that spermine synthase (SMS) was significantly upregulated in tumor cells, which correlated positively with immunosuppressive microenvironments and predicted poor survival in hepatocellular carcinoma (HCC) patients. Via “subcutaneous” and “orthotopic” HCC syngeneic mouse models and a series of in vitro coculture experiments, we identified elevated SMS level in HCC cells played a role in immune escape mainly through its metabolic product spermine, which induced tumor-associated macrophage (TAM) reprogramming and subsequently corresponded with a decreased antitumor functionality of CD8+ T cells. Mechanistically, we discovered that spermine reprogrammed TAM mainly by activating the PI3K-Akt-mTOR-S6K signaling pathway. Spermine inhibition in combination with immune checkpoint blockade effectively diminishes tumor burden in vivo. Our results expand the understanding of the critical role of metabolites in regulating cancer progression and anti-tumor immunity, and open new avenues for developing novel therapeutic strategies against HCC.